Beobachtungsplan, NIS 572: Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7)

Datei

• Artikel "Beobachtungsplan, NIS 572: Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7)"Herunterladen(PDF, 2MB, Datei ist nicht barrierefrei)